NUVL
Price:
$83.85
Market Cap:
$5.96B
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-gener...[Read more]
Industry
Biotechnology
IPO Date
2021-07-29
Stock Exchange
NASDAQ
Ticker
NUVL
According to Nuvalent, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.63%. This represents a change of 301.06% compared to the average of -7.14% of the last 4 quarters.
The mean historical ROE of Nuvalent, Inc. over the last ten years is 12.96%. The current -28.63% ROE has changed -320.93% with respect to the historical average. Over the past ten years (40 quarters), NUVL's ROE was at its highest in in the December 2020 quarter at 21.01%. The ROE was at its lowest in in the March 2020 quarter at -167.05%.
Average
12.96%
Median
-15.84%
Minimum
-18.02%
Maximum
68.43%
Discovering the peaks and valleys of Nuvalent, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 13.73%
Maximum Annual ROE = 68.43%
Minimum Annual Increase = -134.98%
Minimum Annual ROE = -18.02%
Year | ROE | Change |
---|---|---|
2023 | -18.02% | 13.73% |
2022 | -15.84% | -2.55% |
2021 | -16.26% | -134.98% |
2020 | 46.47% | -32.09% |
The current ROE of Nuvalent, Inc. (NUVL) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-16.71%
5-year avg
12.96%
10-year avg
12.96%
Nuvalent, Inc.’s ROE is less than DICE Therapeutics, Inc. (0%), less than Arcellx, Inc. (56.07%), greater than Vaxcyte, Inc. (-8.28%), greater than Viridian Therapeutics, Inc. (-23.53%), greater than Ventyx Biosciences, Inc. (-45.47%), greater than Cullinan Oncology, Inc. (-54.94%), greater than Kiniksa Pharmaceuticals, Ltd. (-26.54%), greater than Replimune Group, Inc. (-2.08%), greater than Ascendis Pharma A/S (-53.12%), less than United Therapeutics Corporation (212.63%), less than Cerevel Therapeutics Holdings, Inc. (19.22%), greater than Travere Therapeutics, Inc. (-98.94%), greater than Structure Therapeutics Inc. (-541.59%), greater than null (-16.40%),
Company | ROE | Market cap |
---|---|---|
0% | $2.27B | |
56.07% | $4.15B | |
-8.28% | $10.85B | |
-23.53% | $1.56B | |
-45.47% | $166.17M | |
-54.94% | $691.16M | |
-26.54% | $1.46B | |
-2.08% | $929.70M | |
-53.12% | $8.35B | |
212.63% | $16.23B | |
19.22% | $8.19B | |
-98.94% | $1.49B | |
-541.59% | $1.64B | |
-16.40% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvalent, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nuvalent, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Nuvalent, Inc.'s ROE?
How is the ROE calculated for Nuvalent, Inc. (NUVL)?
What is the highest ROE for Nuvalent, Inc. (NUVL)?
What is the 3-year average ROE for Nuvalent, Inc. (NUVL)?
What is the 5-year average ROE for Nuvalent, Inc. (NUVL)?
How does the current ROE for Nuvalent, Inc. (NUVL) compare to its historical average?